
Strategic Risk Register

								Applicable Strategic Priorities	•
District	There is a ri	sk that Public Health Wale	s will be	unable to fulfil its str	ategic	objectives because	it does	Influencing the wider determinants of health	\mathbf{X}
Risk 1		ave the correct numbers o	Improving mental well-being and building resilience	\boxtimes					
			Promoting healthy behaviours	\mathbf{X}					
		Sponsor a	nd Assu	rance Group				Securing a healthy future for the next generation through a focus on early years.	\boxtimes
Executive	e Sponsor	Neil Lewis, Acting Directo	or of Peo	Protecting the public from infection and	X				
Assurin	g Group	People and Organisation	al Develo	opment Committee (Curren	ly the Board)		environmental threats to health	
		In		Supporting the development of a sustainable health and care system focused on prevention and early intervention	\boxtimes				
Date	ate	Likelihood:	4	Impact:	4	Score:	16	Building and mobilising knowledge and skills to improve health and well-being across Wales	\boxtimes

	Sponsor and Assurance Group		through a focus o
Executive Sponsor	Neil Lewis, Acting Director of People and Organisational Development		Protecting the pul
Assuring Group	People and Organisational Development Committee (Currently the Board)		environmental thr
		J Г	

	Inh	erent R	Risk				and early interven
Date	Likelihood:	4	Impact:	4	Score:	16	Building and mob improve health an

		Risł	<pre> Score </pre>			Risk Decision	Control Summary	No. of Controls	20		
Curre	Current Risk Target risk							No. of Assurances	43		
							TREAT	A		Weak Assurances	9
Likelihood	Impact	ct 16 Likelih		Impact	8	IREAT	Assurance	Breakdown of Total	Moderate Assurances	2	
	4		2	4			Summary	Assurance Rating	Strong Assurances	8	
	·							-	No Assurance	3	
									Not assessed	21	



Dashboard

Strategic Risk Register

	EXISTING CO	ONTROLS		Level	at whi	ch the rovideo		ance	
No.	Control	Exec Owner	SOURCES OF ASSURANCE	Team / Division / Project /Program me	Director ate Team / Exec Lead	Busines s Exec Team / Sub Groups	Commit tee / Sub group	Board	Assessment of each Assurance
1.1	People Strategy		Bi Annual Reports to PODC / Board on achievement of actions			x	x	х	Not Assessed
1.2	Organisational Workforce plan to support IMTP and first three years of People Strategy		Updates provided alongside People Strategy reports to the Executive Team and Board			x	x	х	Strong
	Corporate succession plan to outline		Talent and succession map	X	X	X	Х		Weak
1.3	(initially) succession into the top three		People Strategy (1)	X	X	Х	X		Not assessed
	tiers		Organisational workforce plan updates (2)	X	X	X	X		Not assessed
		Acting Director – People and Organisational Development	Corporate recruitment plan (approved by Board Jan 2020)			x	x		Strong
1.4	Recruitment plan and tracker		Recruitment plans being managed through the workstreams within the Response Plan.		x	х			Not assessed
			COVID Recruitment Plan (to GOLD)		X	Х			Not assessed
			Weekly workforce subgroup meeting minutes, actions and reports. (Sitrep Gold)	x	x	x			Not assessed
1.5	Structured approach to funding learning and development - deferred until 2021/2022 budgets								
4.0	Directorate level plans focussing on		Directorate workforce plans (focus on BAU);	X	X	X			Strong
1.6	change, development and recruitment. These will include areas of focus such as Microbiology and radiology	All	Recruitment plans directly linked to COVID managed via the routes noted in 4.						Not assessed
1.7	Job families	Acting Director – People and Organisational Development	Papers and minutes from the Job Families group and one to one meetings	x	х				Weak
1.8	Professional appraisal and revalidation processes in place, linked through relevant bodies.	Executive Director of Quality, Nursing and Allied Health Professionals / Executive Director of Public Health Services/Medical Director	Integrated Performance Report		x	x	x		Strong
1.9	Training and succession plan in	Acting Director – People and Organisational Development/ Executive Director of Quality, Nursing and	Training and succession plan		x		x		Strong
	conjunction with Deanery/ HEIW	Allied Health Professionals / Executive Director of Public Health Services/Medical Director	Stats through Integrated Performance Report		x	x	x		Strong
			Programme content	Х	X				Weak
1.10	Learning and Development	Acting Director – People and Organisational	Manager's Induction	X	X				Weak
		Development	Attendance registers	X	X	X			Weak
			ESR reports	X	X				Weak

Strategic Risk Register

- Risk 1

	EXISTING C	ONTROLS		Level		ch the rovideo		ance	
No.	Control	Exec Owner	SOURCES OF ASSURANCE	Team / Division / Project /Program me	Director ate Team / Exec Lead	Busines s Exec Team / Sub Groups	Commit tee / Sub group	Board	Assessment of each Assurance
			Staff survey reports	X	X				Weak
			NCC training packages and records (COVID)	X	X				Not Assessed
1.11	PDRs both My Contribution and Job		IPR and compliance reports	X	X	X	Х	Х	Moderate
	Plans	All	My Contribution Action Plan						Not assessed
			NHS Staff Survey Results (scheduled late 2020 subject to Ministerial approval)	x	x	x	x	X	Strong
1.12	Staff Engagement Surveys	Acting Director – People and Organisational Development / All	PHW Wellbeing and Engagement Survey Results (during COVID)	х	х	х		Х	Not assessed
			Workforce Reports	X	X	X	Х		Not assessed
			Meeting papers from Wellbeing and Engagement Group (est. July 2020)	x	x	x	x		Not assessed
		Published results and documented actions pla							Not assessed
1.13			Staff survey results (as per 12)	X	X	X	X		Moderate
1.13			Absence data reporting via IPR	X	X	X	X		Not assessed
	Wellbeing	Wellbeing		x					Not assessed
			COVID Absence Dashboard	x	x	x			Not assessed
1.14	Establish Approach to widening access for potential (often younger) employees	Acting Director – People and Organisational							
1.15	Integrated Performance Report	Development	Exception reporting on key measures that have not been reached such as turnover and absence with plans of action attached		x	x	x	x	Strong
1.16	Welcome, Engage, Network and Develop		Induction content (on hold due to COVID)	X	X				No Assurance
1.10	days (on hold due to COVID)		Attendance registers (on hold due to COVID)	X	X				No Assurance
1.17	Behaviours framework		Values-aligned behaviours framework piloted, approved and launched (on hold to COVID)		x	x			No Assurance
1.18	Public Health Practitioner Registration	Acting Director – People and Organisational	Take up reports	X	X				Weak
_	Scheme	Development / Executive Director of Health and Wellbeing	Number of staff registered	x	x				Weak
4.40	Trade Unions; Staff Networks; Equality,	Acting Director – People and Organisational	Weekly informal meetings with Trade Unions		x				Not assessed
1.19	Diversity & Inclusion (COVID)	Development	Local Partnership Forum meeting minutes and reports			x			Not assessed
			Mobilisation status dashboard		X	X			Not assessed
1.20	Workforce Mobilisation (COVID)	Transitional Director - Knowledge	Skills surveys		X	X			Not assessed
			Reverse mobilisation process		X	X			Not assessed

Control Number	Gaps in controls	Gaps in assurance		Action Plan		Due Date					
			1	Consultation with key stakeholders. People Strategy linked to IMTP.	_		People Stra Board in Ja				
1.1	People Strategy to support the PHW	Project Plan relating to transformation of People and OD	to transformation of	to transformation of People and OD	to transformation of People and OD	to transformation of People and OD	2	Deliverables incorporated into People and OD departmental plan and linked to team objectives		October 2020	production developed. Interim repo being prepa
	long term strategy	Directorate with appropriate time- scales and outcomes	3	New People and OD team structure to be developed in consultation with the organisation to ensure alignment with people strategy		November 2020	Interim tear implementa Skills asses Team revie owing to Di				
	_	Quality assurance of	4	Consultation with key stakeholders and workforce planning sessions facilitated.			All actions I draft plan in				
1.2	Organisational workforce plan	plan	5	Workforce plans returned to People and OD to review Trends and themes identified.		November 2020	An interim r 2020 being				
		Directorates	Directorates Draft to be quality assured by Skills for Health to ensure a coherent narrative.								
	An implemented corporate		8	Draft to be submitted to Execs on 27 November. Establish a regular process going forward into 2021/22	People and Organisational Development		Broader wo recommenc programme				
1.3	approach to succession	Quality assurance of plan	9	In the process of finding a date for these wider/ moderation discussions.		October 2020					
	planning and talent management		10	Linking to wider work and timescale with HEIW.							
	management		11	Finalised talent and succession map to be completed.							
1.4	No tracking tool against corporate recruitment plan	Gaps in data provided	12	Continue work as part of business process improvement activity in this area.		November 2020	The People Recruitmen information Directorates As well as in spreadshee This information allowing IT recruitment Finance on As part of the investment a Corporates all Directorates				

Action Plan

Progress

rategy has been completed and approved at anuary 2020. This has been sent for final h (**COMPLETE**) and a launch plan is being l.

port on implementation within COVID context pared for Board

am structure in place to support tation of the People Strategy - **COMPLETE**.

essment undertaken August and Senior ewing options for structure herein (delayed Director leaving)

listed have been completed with a working in place. This was delayed due to COVID. report is being prepared and approach for g determined.

ork on hold due to COVID, however adation with Director/CEO for HEIW the commencing Oct 2020

e and OD Directorate maintain a nt spreadsheet which is populated with n on planned recruitment obtained from es.

information on posts to be advertised, this set includes information on location of posts. nation is shared with Ops and Finance,

and Estates to also plan for this

nt. P&OD are working closely with Ops and n this 'growth plan'.

the business process improvement work, an t bid may be considered in order to purchase te Recruitment Tracker which would enable rates to directly input their recruitment plans

Control Number	Gaps in controls	Gaps in assurance		Action Plan		Due Date	
							A recruitme we are seel
1.5			13	Development of a structured approach to funding learning and development -		April 2021	delivery of p Executive T how learnin organisation HP respons
1.10	Management Induction	Lack of assurance around knowledge and skills to deliver within a management role	14	Pilot management induction following consultation with key stakeholders		November 2020	Second ind learning set 2020 (evalu so far prese Reviewing a confirmation mental heal
1.11			15	Undertake Quality audits (planned)	Acting Director of	Q4 2020/2021	On track.
			16	Revise My Contributions Policy	People and Organisational Development	October 2020	On track.
			17	Draft approach to be developed making links to Well- being of Future Generations Act by improving social, economic, environmental and cultural wellbeing			Our approa workforce is
		Cono in plan for	18	Joined up approach to collaboration with schools, colleges and universities;			currently or Approach a
1.14	Approach to young people	Gaps in plan for delivery and join up with Well-being of Future Generations	19	Young Ambassador Programme; Careers Networks; Work-placements scheme; Internships; Apprentices; Graduate Schemes		April 2021	Executive (held during
		Act	20	Discussions to be taken forward by Deputy Director of People and OD with directorates			Apprentices may not pic
			21	Determine appropriate way forward with collaborative partners with clear outcomes and evaluation			
			22	Deliver regular management induction sessions Evaluation			

Action Plan

Progress

nent plan is in in place linked to COVID, and eking additional resources to manage the f plan.

Team presented with recommendation for ing and development is funded across the on. Discussion and decisions on hold due to nse.

duction cohort underway with final action ets from the pilot group scheduled for June iluation to follow). Summary of pilot findings sented to SLT in December 2019.

available learning platforms, awaiting on of non-pay budget to provide managing alth training

bach to young people and engaging the future is being developed by our graduate who is on placement with the People and OD team. and options mapped and paper presented to Team including younger persons strategy ng COVID)


eship providers already warning programmes ick up until 2021.

	There is a risk that Public Health Wales will cause significant harm to patients, service users or staff		A
Risk 2	members. This will be caused by misdiagnosis or incorrect identification of serious health conditions,	1	Influenci
	timeliness of service provision, the provision of inappropriate clinical advice or the failure of staff to follow correct procedures.	ſ	Improving

	Sponsor and Assurance Group	Securin
Executive Spon	sor Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals	generat Protecti environi
Assuring Grou	Quality, Safety and Improvement Committee (patient and service user) People and Organisational Development Committee (staff) (temporarily being reported directly to Board)	Support health a and ear

	Innerent Risk														to improve hea Wales	Ith and well-being across						
Date			Lil	kelihood	:	5	Impact	:		5	Sco	core: 25			Wales							
		Risk	Score	Risk Decision						Control Summary No. of C			o. of C	or	ntrols	23						
Curre	ent Risk		Tar	Target risk						No. o			. of Ass	su	rances	62						
Likelihood	Impact		Likelihood	Impact			Treat			Assur	ance	Bro	akdow	n	of Total	Weak Assurances	15					
		20	•		15	Πσαι		ITEal	Ileal		Ileal				Summary				eakdown of Total		Moderate Assurances	22
4	5		3	5						-		A9	Suranc	,e	Rating	Strong Assurances	21					
																No assurance	4					

Assurance Breakdown per Control



App

cing t ring m resilience Promoting h

ing a ation t

cting th nmen orting

and arly int

Building and

Dashb	board	
olicable Strategic Pi	riorities	
the wider determinants of	of health 🛛 🔀]
nental well-being and bu	ilding 🛛 🖂]
nealthy behaviours]
healthy future for the ne through a focus on early]
he public from infection tal threats to health	and]
the development of a su care system focused on tervention]
d mobilising knowledge a nealth and well-being ac]

	Existing Control			Lev	el at whic pro	h the As		e is	Assessment
No.	Control	Exec Owner	Sources of Assurance	Team / Division / Project	Directorat e Team / Exec Lead	Busines s Exec Team / Sub Groups	Commit tee / Sub group	Board	of each Assurance
			Quality Indicators Performance Monitoring as reported in the Integrated Performance Report	X	Х	Х		Х	Moderate
			Health and Care Standards regular Monitoring at Board - IPR – ongoing monitoring of implementation		Х	Х		Х	Moderate
			Health and Care Standards - Arrangements / system in place.	X	Х	Х	Х		Strong
2.1			Corporate Safeguarding Annual Report			Х	Х		Weak
	Corporate Quality Management systems		Infection Control Annual Report			Х	Х		Weak
			PTR Quarterly Report (IPR Monthly)			Х	Х	Х	Strong
			PTR Annual Report			Х	Х		Moderate
			Quarterly Alert exception Report			Х	Х	Х	Moderate
			Annual Quality Statement		Х	Х	Х	X	Strong
		Executive Director Quality,	Quality and Clinic Audit Plan - Annual Report and update reports			Х	Х		Strong
2.2	Professional Degulation	Nursing and Allied Health	Annual report to People and OD Committee /QSIC		Х	Х	Х		Strong
2.2	Professional Regulation		Quality Review Visit by medical revalidation support unit	X	Х	Х	Х		Moderate
			Putting Thing Right - Report			Х	Х		Moderate
2.3	Insident Departing Management System		Putting Thing Right - Annual			Х	Х		Strong
2.3	Incident Reporting Management System		Organisational Annual Report – (Reported to WG)			Х	Х		Strong
			SI reporting as occurs			Х	Х	Х	Moderate
2.4	Directorates Mid & end year review process		Directorates Mid and year end reports		Х	Х		X	Strong
			HIW Inspections			Х	Х	Х	Strong
			HSC			Х	Х		Strong
2.5	External Reviews		JAG accreditation	X	Х	Х			Weak
			UKAS Accreditation	X	Х	Х	Х		Weak
			Audit Wales Structured Assessment	X	Х	Х	Х	X	Strong
2.6	Health Care Support worker programme		Update reports (PODCOM) (Annual)		Х	Х	Х		Moderate
			Medicines Management Policy			Х	Х		Weak
2.7	Medicines Management System	Executive Director of Dubli-	Medicines Management Procedure			Х	Х		Weak
		Executive Director of Public	Pharmaceutical SLA with Cardiff & Vale University Health Board			Х			Weak
		Health Services/Medical Director / Executive Director	Medical Devices Policy			Х	Х		Weak
		Quality, Nursing and Allied	Medical Devices Procedure			Х	Х		Weak
2.8	Medical Devices Arrangements	Health	Medical Devices Registers (Microbiology Laboratories)	X					Weak
		Ticalui	Medical Devices Screening Division Register	X					Weak
			Medical Devices Register (Corporate)	Х					Moderate
2.9	Public Health Services QMS	Exec Director of Public Health Services/Medical	Local Audit	X					Moderate
		Director	Vertical & Horizontal Audits of Microbiology Laboratory Services	X					Strong
		Executive Director of Public	Defined failsafe task and finish groups (papers and notes) to review screening programmes against policy	X					Weak
2.10	Failsafe systems	Health Services/Medical Director	SI reporting as occurs to Board and quarterly to QS&I Committee			Х	Х	Х	Moderate
		Director	Screening Division – Standard Operating Procedures (document development, review and approval)	X					Moderate

Controls

			Microbiology Division – Standard Operating Procedures (document development, review and approval)	X					Strong
		Executive Director of Public	Stabilisation Action Plan process Update on hold due to Covid	X	Х	X			No Assurance
2.11	Microbiology Stabilisation Programme	Health Services/Medical Director	Stabilisation Action Plan: Progress Update Reports to QSIC on hold due to Covid			X	х		No Assurance
			Reports to Board (AD HOC) on hold due to Covid			Х		Х	No Assurance
			Microbiology Programme Board Reports on hold due to Covid			Х			No Assurance
2.12	Recruitment Procedures and Checks policy		Appropriate job descriptions	Х					Weak
2.13	Statutory & Mandatory training Competency and role based training and Regulatory standards		Included in Integrated Performance Report			x		х	Strong
2.14	People & OD Performance Information and Reports (Including Detailed recruitment MI)		Included in Integrated Performance Report			х		X	Strong
2.15	Personal Development Reviews 'My Contribution'	Acting Director of People &	Included in Integrated Performance Report			x		X	Strong
2.16	Workforce Plan	Organisational Development	Reports to People & OD Committee (as part of the IMPT process)				x		Moderate
			Directorate workforce plans		Х	Х			Weak
2.17	Staff Survey		Staff Survey results			Х	Х	Х	Moderate
2.17	•		Engagement Reporting			Х	X		Weak
2.18	Leadership and Management development Programme		Performance Data Report		Х	Х		X	Strong
2.19	Occupational Health provision		Reports to QS&I Committee and POD Committee				Х		Weak
			Policy, Procedures and other written control documents Policy			Х	X	X	Moderate
			Policy, procedures and other written control documents Procedure		Х	x			Moderate
2.20	Policies	Deard Convetery & Lload of	Policy register report to Audit and Corporate Governance Committee on compliance with Policies		Х	x	x	x	Moderate
		Board Secretary & Head of Board Business Unit	Policy register report of relevant policies to each Board Committee			x	x		Moderate
			Internal audit plan			Х	Х		Moderate
2.21	Internal Audit Programme		Audit reports as a result of the annual programme		Х	Х	Х		Moderate
2.21	internal Audit Flogramme		Annual head of internal audit report			Х	Х	Х	Moderate
			Internal audit action log (and follow up of actions)		Х		Х		Moderate
2.22	Department Standard Operating Procedures	Exec Team (report via Board Secretary)							
2.23	Health & Safety plan	Deputy Chief Exec/ Exec Director of Operations & Finance	Health and safety action plan and associated reports	х	Х		x		Moderate

Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
		Lack of assurance mechanism in relation to effectiveness of an Integrated Governance Framework	1	Complete a gap analysis on current integrated governance arrangements.		December 2020	Due to the emergency re unable to progress, as a mobilised to work on the action, the scope of this COVID, resource issues focus the analysis. A re added for completion for
NEW	NEW Absence of existing coherent and comprehensive Integrated Governance Framework		2	Develop a Quality assurance dashboard		To be determined	The draft Quality assura format for the PTR report to the Quality, Safety an 2020 for consideration. this action was complete improve the dashboard a superseded by the deve Dashboard.
			3	Ensure the Quality Assurance Dashboard includes measures / indicators to include the IPC and safeguarding indicators		December 2020	On track.
			4	Develop an Integrated Governance Model and Implementation Plan	Executive Director Quality, Nursing	April 2021	Integrated Governance agreed and commenced Covid-19 response.
			5	Complete a Governance Stakeholder mapping exercise	and Allied Health Professionals	December 2020	Work has commenced to governance stakeholder 19 response but will reco constraints.
2.1		Gaps in consistently applied, monitored and reported quality and improvement measures aligned to strategic priority outcomes and	6	Develop and approve Quality and Improvement Strategy		November 2020	Work is ongoing to enga Improvement Strategy a identify Quality and Impr been developed. This work has been pau having been redeployed emergency response. A content of the strategy, a with directorates. This w in November 2020.
		integrated performance report				To be determined	Draft indicators presenter refine the quality indicate order that they can be in assurance dashboard.
		Gaps in ownership of improvement actions at	8	Support ownership in Directorates and Divisions in identifying		February 2021	Self-assessment templa responsible owner for ea was further explained du

Action Plan

Progress

response to Covid-19 this work has been all available people resources have been he response. Within the current context, this is work needs to be revised to focus on es, and Governance 'Hotspots' to target and revised date of December 2020 has been for this work.

rance dashboard in conjunction with a revised ort, has been developed and will be presented and Improvement Committee on 11 February . The management dashboard component of ted and further work is ongoing to further d and PTR report. .This work has been velopment of the Performance and Assurance

e models and implementation plan will be ed. This work has been impacted by the

to identify organisational integrated ers. This work has been impacted the Covidcommence within the available resource

gage key stakeholders on the Quality and and Executive Directors have been asked to provement champions and the role profile has

used due to the Quality Improvement team ed to other duties to support the Covid-19 A meeting was held in August to agree the , and the first draft will be shared and engage will be reported to BET in October, and QSIC

ated to Gold. Further work to be undertaken to ates by working with Stage 2 workstreams, in incorporated into the performance and

late has been amended to ensure a each improvement action is identified. This during a workshop in October 2019, and again

Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date		
		Directorate for the Health Care Standards Self- Assessment.		improvements and enacting action plans			at the Peer Review sess will continue to be monit Performance Report. A Standards report was re Improvement Committee A revised process for 20 reflect the current COVI February 2021, and QS	
		Gaps in consistently applied KPIs for IPC and Safeguarding	9	Develop Quality Management Dashboard to include assurance for IPC and Safeguarding to provide regular reporting to QSIC		November 2020	Work is progressing to id and these will be include Assurance Dashboard v as the safeguarding lead 19 emergency response A draft of the IPC and S the Quality, Safety and I discussion.	
		Development of Quality and Clinical Audit Plan was not fully aligned with adherence to SOPs and improvement activity.	10	Further develop Quality and Clinical Audit Plan to ensure alignment with adherence to SOPs and improvement activity for next audit planning cycle	Executive Director Quality, Nursing and Allied Health Professionals	May 2021	The Quality and Clinical Quality, Safety and Impo September 2020. The p 2020/21, and a 6 month The 2021/22 Quality and in May 2021.	
2.3	Lack of systematic and embedded approach to reflecting and learning from raising concerns (Whistleblowing)	Lack of assurance mechanism for 'raising concerns' (Whistleblowing)	11	Implement an organisational approach to disseminating and raising awareness of the 'Raising Concerns' (whistleblowing) policy	Board Secretary and Head of Board Business Unit	March 2021	This work has been tem response but will be res policy, dedicated intrane	
2.7	Absence of up to date and accurate medical devices register		12	See action plan for 2.8 (Actions 14,15,16)				
2.8	Lack of systematic assurance mechanism in relation to management of		13	Strengthen organisational governance of medical devices (including registers)	Executive Director of Public Health Services/Medical Director Executive Director	November 2020	Work has completed to The next step is to revie This work has not proce because of competing d Externally commissioned actions. The date provid work.	
	management of medical devices	•	•		Review the Medical Devices Policy and Procedure (due to Medical Devices and IVD Regulations)	Quality, Nursing and Allied Health Professionals	March 2021	This work has been tem response but will be res of March 2021 has been

Action Plan

Progress

ssion in January 2020. Improvement actions nitored on a quarterly basis via the Integrated A report to close the 2019/20 Health and Care received by the Quality, Safety and ee on 7 September 2020.

2020/21 will be re-issued and adapted to /ID context. This will be reported to BET in SIC thereafter.

o identify KPIs in both safeguarding and IPC ded in the Quality Management and I when finalised. This work has been paused ead has been redeployed to support the Covidse.

Safeguarding indicators will be presented to d Improvement Committee in November for

al Audit Plan for 2020/21 was approved by the provement Committee at its meeting in a plan will be updated and reviewed during thly report will be provided to QSIC.

nd Clinical Audit Plan will be received at QSIC

mporarily paused due to the Covid-19 esumed in the coming weeks. The All Wales net page and advice remains in place.

o review the reviewing medical asset register. iew within Public Health Services.

ceeded since the beginning of the year demands in key staff to the COVID response. and support will be required to complete these ided refers to the intent to commission this

mporarily paused due to the Covid-19 esumed in the coming weeks. A revised date en added for completion of this work.

Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
			15	Scope non-clinical areas to ensure that no devices remain unaccounted for in the governance arrangements		November 2020	Work has completed to The next step is to revie This work has not proce because of competing of Externally commissione actions. The date provid work.
2.10	Delivery of the National Health Protection Service Transformation Programme		16			See Action ir	n Risk 3
2.20	Process inconsistently applied for updating and disseminating new/ updated policies		17	Development of existing procedure to ensure a consistent approach to policy development, approval and communication that is timely and effective.	Board Secretary and Head of Board Business Unit	January 2021	This is in progress. The written control documer Board. The procedure w will then commence on
2.21	Clear picture of all audit related activity across the organisation (corporate & clinical)		18	Develop a comprehensive overview that collates and summarises all audit activity planned for April 2021 onwards – repeat on an annual basis	Board Secretary and Head of Board Business Unit / Executive Director Quality, Nursing and Allied Health Professionals	April 2021	
2.22	Confirmation of appropriate processes being in place within each directorate for updating and	Gap in assessment of adherence with SOPs and testing using Quality and	19	Conduct Audit of what Standard Operating Procedures (SOPs) processes are in place in each directorate that meets a required standard.	Executive team members (reported via Board Secretary and Head of	February 2021	This work commenced p and will now be resume
	disseminating new/updated standard operating procedures	Clinical Audit.	21	Test compliance and adherence with SOPs	Board Business Unit)	April 2021	
new			22	Compliance with minimum standards for IPC (for reactivation of Screening Services)	Executive Director	October 2020	
new				Once for Wales Datix system to be implemented by March 2021	Quality, Nursing and Allied Health Professionals	March 2021	The implementation of t to March 2021 subject to timeline. Public Health V implications.

Action Plan

Progress

to review the reviewing medical asset register. view within Public Health Services.

ceeded since the beginning of the year g demands in key staff to the COVID response. ned support will be required to complete these vided refers to the intent to commission this

ne Policy for policies, and procedures and other ents has been revised and approved by the will be consulted on during the Autumn. Work on improving communication and compliance.

d prior to COVID within Public Health Services, ned.

f the entire system has been brought forward to Public Health Wales agreed the WG Wales are considering the resource

Risk 3	There is a risk that Public Health Wales will fail to deliver a sustainable, high quality and effective infection and screening services. This will be caused by a lack of sufficient workforce capacity; over-reliance on existing	Appli	
	systems/procedures, lack of sufficient change capacity and an estate and infrastructure which is not fit for	Influencing the wi	
		purpose.	Improving mental resilience

	Sponsor and Assurance Group	Promoting healthy	
Executive Sponsor	Dr Quentin Sandifer, Executive Director Public Health Services / Medical Director	Securing a health through a focus o	
Assuring Group	Quality, Safety and Improvement Committee Audit and Corporate Governance Committee	Protecting the pu environmental th	

Inherent Risk									
Date		Likelihood:	5	Impact:	5	Score:	25		

			Risk Score			Risk Decision				
Curi	rent Risk		Та	arget risk						
Likelihood	Impact	20	Likelihood	Impact	15	TREAT				
4	5	20	3	5	15					

Dashboard

Applicable Strategic Priorities	
Influencing the wider determinants of health	
Improving mental well-being and building resilience	
Promoting healthy behaviours	
Securing a healthy future for the next generation through a focus on early years.	
Protecting the public from infection and environmental threats to health	\boxtimes
Supporting the development of a sustainable health and care system focused on prevention and early intervention	\boxtimes
Building and mobilising knowledge and skills to improve health and well-being across Wales	

	Existing	g Control		Level at which the Assurance is provided to						
No.	Control	Exec Owner	Sources of Assurance	Team / Division / Project / Program me	Directo rate Team / Exec Lead	Business Exec Team / Sub Groups	Committ ee / Sub group	Board		
	Policies and Procedures *		Corporate Policy and Control Document Reviews – corporate register update reports	X	Х	Х	Х	Х		
	(document development, review and approval)	Evenutive Disentes Dublic Lineth	Health Protection Division – Standard Operating Procedures (document development, review and approval)	x	х					
3.1	* including Standard	Executive Director Public Health Services / Medical Director	Microbiology Division – Standard Operating Procedures (document development, review and approval)	x	x					
	Operating Procedures		Screening Division – Standard Operating Procedures (document development, review and approval)	x						
3.2	UK Accreditation Service		Reports to Quality, Safety and Improvement Committee		X	Х	X			
0.2	(UKAS) -Accreditation		Action Plan and Reports – Divisional Senior Management Teams	Х						
		Executive Director Public Health	Medical, Nursing and Multi-Disciplinary Staff Revalidation - Annual Report to People and Organisational Development Committee / Quality, Safety and Improvement Committee				x			
	Professional Regulation –	Services / Medical Director	Quality review visit by Medical and Multi-Disciplinary Revalidation support unit			Х	Х			
3.3	Medical, Nursing and	Executive Director Quality,	Quality Indicators Performance Monitoring			Х	x	х		
	Multi-Disciplinary Staff	Nursing and Allied Health	Monitor registered and revalidation		x					
		Professionals	Medical, Nursing and Multi-Disciplinary Appraisal Process – Quality Indicator			Х	X	Х		
			Medical Job Planning Process – Quality Indicator			Х		Х		
	Management System Executive Director		Update Reports to Health and Safety Group	Х	Х	Х	Х			
2.4		Deputy Chief Executive and Executive Director Operations and Finance	Health and Safety Action Plan		Х	Х	Х			
3.4			Microbiology Division Health and Safety Sub-Groups (reports to Divisional SMTs)	Х	Х					
			Update Reports to People and Organisational Development Committee		Х	Х	Х			
			Business Continuity Action Plans (Public Health Services)	Х	Х	Х				
			Emergency Planning and Business Continuity Group Meeting minutes		Х					
3.5	Business Continuity		Learning and Development Prospectus for Business – Training and Exercise reports to Emergency Planning and Business Continuity Group		x					
5.5	Arrangements (for Public Health Services)	Services / Medical Director	Emergency Planning and Business Continuity Annual Work Plan		x					
			Emergency Planning and Business Continuity Documentation (regular review and update)	X	X					
			Emergency Planning and Business Continuity Report - Audit and Corporate Governance Committee	х			x			
			National Health Protection Service Transformation (Programme) Board - Meeting Minutes and Papers	x	x	х				
	National Health		National Health Protection Service Transformation Programme Plan(s)	x	x	х				
3.6	Protection Service (NHPS) Transformation	Executive Director Public Health Services / Medical Director	Microbiology Stabilisation Plan	x	x	х				
	Programme (including Microbiology		Stabilisation/Transformation Reports to QSI Committee and Board			х	x	х		
	Stabilisation)		Divisional Assurance Reports to DLT (inform Executive Director Reports – see 3.7)	x	x					

	Existing	g Control		Level at	t which t	he Assura to	surance is provided		
No.	Control	Exec Owner	Sources of Assurance	Team / Division / Project / Program me	Director ate Team / Exec Lead	Business Exec Team / Sub Groups	Committe e / Sub group	Board	
			Reports provided to SMTs and DLT	Х	X				
			Public Health Services Directorate Leadership Team (DLT) meeting minutes and papers (bi-monthly)	x	x				
0.7	Directorate Business and	Executive Director Public Health	Senior Management Team (SMT) Meeting minutes and papers (monthly)	Х					
3.7	Financial Management Systems and Processes	Services / Medical Director	Directorate Leadership Team Finance Sub-Group meeting minutes and papers (monthly)		Х				
	Systems and Flocesses		Divisional Assurance Reports to DLT (inform Executive Director Reports)	Х	Х	Х			
			Executive Director Reports (to Executive and Board)			Х		X	
			Mid and End of Year Review Reports (Executive scrutiny)		x	Х			
			Health and Care Standards Reporting		Х	Х	Х	X	
			Reporting on Quality Impact Framework Implementation Plan		Х	Х	Х		
			Local Audits	Х	Х	Х	Х		
	Quality Management Systems	Executive Director Public Health Services / Medical Director	Vertical and Horizontal Audits of Microbiology Laboratory Services	Х					
3.8	(including informatics and information managements systems)	Executive Director Quality,	Quality and Clinical Audit Plan – Annual Report		х	х	Х		
0.0		Nursing and Allied Health	Quality and Clinical Audit Plan – Bi-annual report to Quality, Safety and Improvement Committee		x	x	х		
			Mid and End of Year Review Reports (Executive scrutiny)		Х	Х			
			Informatics Programmes/Project Board Reports (minutes, papers and reports via Annual Plan)	x	x	х			
		Executive Director Public Health	Putting Things Right - Annual Report			Х	Х		
3.9	Incident Reporting Management System	orting Services / Medical Director	Putting Things Right - Quarterly Alert Exception Report (Quality, Safety and Improvement Committee)			х	х		
	Management Oystern		Serious Incident Reporting (Quarterly) to Quality, Safety and Improvement Committee			х	x		
			Defined failsafe task and finish groups to review screening programmes against policy	Х	Х	Х	Х		
			Review of serious incidents to determine if further failsafe required (Microbiology and Screening)	x	x	x			
3.10	Failsafe Systems	Executive Director Public Health Services / Medical Director	Screening Division – Standard Operating Procedures (document development, review and approval)	x	x				
			Microbiology Division – Standard Operating Procedures (document development, review and approval)	x	x				
			Health Protection Division – Standard Operating Procedures (document development, review and approval)	x	x				
		Executive Director Public Health	Infection Reporting Dashboard	Х	Х	Х			
	Infection, Prevention and	Services / Medical Director	Health Protection Situational Awareness Reports – (monthly report to Executive)	Х	Х	Х			
3.11	Control Systems	Executive Director Quality, Nursing and Allied Health	Public Health Wales Infection, Prevention Control Group – minutes and papers (minutes received by Quality, Safety and Improvement Committee)	x	x	х	х		
		Professionals	Agreed criteria for escalation (reviewed on an annual basis)	X	x	Х			

Controls

	Existing	g Control			Level at which the Assurance is provided to							
No.	Workforce/Recruitment Planning Executive Director Public Health Services / Medical Director DESW Optimisation and Transformation Programme Image: Comparison of the service of the se	Sources of Assurance Te Divi Pro Pro Or		Director ate Team / Exec Lead	Business Exec Team / Sub Groups	Committe e / Sub group	Board					
	9	Executive Director Public Health	Reports of progress against Workforce Plans	X	X	X						
3.12			Reports to the People and Organisational Development Committee (part of annual Integrated Medium Term Plan planning cycle)			х	x					
			Health Protection and Microbiology Workforce subcommittees minutes and papers (report to Senior Managements Teams)	x								
	DESW Optimization and		Monitoring progress against plans (reports)	x	x	Х						
3.13	•		Divisional Assurance Reports to DLT (inform Executive Director Reports – see 3.7)		X							
3.13			Optimisation/Transformation Reports to Quality, Safety and Improvement Committee and Board			х	х					

Control No.	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
3.4			1	Delivery of Estates Action Plan and Health / Safety Action Plan	Deputy Chief Executive / Executive Director of Finance and Operations		Ongoing delivery relation to Micro relation to HSE notices removed
3.5	Approval of Business Continuity Plans	Assurance reporting to Audit and Corporate Governance Committee	2	Strengthen arrangements for approval of Business Continuity Plans and assurance reporting	Executive Director Public Health Services / Medical Director	To be determined	No further progra to the organisati COVID-19 pand The Business Co organisation hav Business Contin maintain critical 2020, the outcor Group to inform allocation. Busin considered by th of the ongoing s
3.7	Resilience of business management systems and processes	Assurance reporting – general (strengthening required)	3	Public Health Services Directorate Governance Review: Action Plan		To be determined	Public Health W COVID-19 pand currently involve within the Public consequence no regard to this ac
3.6			4	Delivery of the National Health Protection Service Transformation Programme		April 2021	No further progra to the organisati COVID-19 pand
3.8		Additional source of assurance for Quality Management Systems, in relation to screening information management systems	5	Implementation of Cervical Screening Information Management System (CSIMS)	Executive Director Public Health Services / Medical Director Deputy Chief Executive / Executive Director of Finance and Operations	December 2020	Work is progress directed to COV disruption of wor the "enhanced re Testing planned NHS England pr be available from

Action Plan

Progress

ery of estate / Health and Safety action plan in robiology Laboratory estate. All actions in E Improvement notices are complete and ed.

gress has been made on this action plan due ation's ongoing "enhanced response" to the ademic.

Continuity Arrangements for all areas of the ave been enacted. A recent assessment of inuity Plans and the resources needed to al services has been undertaken in March ome of which was presented to the Gold in decision-making concerning resource iness Continuity considerations are regularly

the Executive Team and Gold Group, as part strategic management of the organisation.

Wales' ongoing "enhanced response" to the idemic is the priority for the organisation and ves the deployment of the majority of resource lic Health Services Directorate. As a no further progress has been made with action plan.

gress has been made on this action plan due tion's ongoing "enhanced response" to the demic.

essing within current capacity that is not VID-19 response, recognising risk to vork with competing urgent priorities to support I response" to the coronavirus pandemic. ed to continue in April 2020 as information that progressing with system so NHAIS may not om December 2020.

Control No.	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
			6	Implementation of risk-based diabetic eye screening		April 2021	This is part of the transformation p
3.10 & 3.13		Gap in assurance relating to failsafe systems in Diabetic Eye Screening Wales	7	Delivery of the DESW Optimisation and Transformation Programme	Executive Director Public Health Services / Medical Director	To be determined	No further progre to the organisatio COVID-19 pande Programme was line with Welsh C Executive Team transformation w restart planning.
			8	Review to ensure that our Screening and Microbiology operating systems are all 'failsafe'		December 2020	Limited progress the organisation' COVID-19 pande

Action Plan

Progress

the delivery of the DESW optimisation and programme as detailed below.

gress has been made on this action plan due ation's ongoing "enhanced response" to the idemic. The Diabetic Eye Screening as temporarily paused on 16 March 2020 in a Government, Chief Medical Officer and m approval. DESW optimisation and will be addressed as part of the DESW g.

ss has been made on this action plan due to n's ongoing "enhanced response" to the demic.

	There is an increased risk as a result of COVID-19 that Public Health Wales will fail to provide the level of system	
	leadership needed to deliver the population health gains articulated in the long term strategy. This insufficient capacity/ resources within the organisation, policy and prioritisation decisions of external agencies and wider social, economic	Influe
	and environmental factors.	Impro

							i remeanighte				
	Sponsor an	d As	surance Gro	oup			, , , , , , , , , , , , , , , , , , ,				
Executive Sponsor	Jyoti Atri, Interim Executive D	irector H	ealth and Wellbeing				Protecting the environmenta				
Assuring Group	Business Executive Team an	Init Executive Director Health and Weilbeing environmenta cutive Team and Board Supporting the Inherent Risk building and r to improve he building and r									
	Inherent Risk										
Date	Likelihood:	5	Impact:	5	Score:	25	to improve he Wales				

			Risk Score		Risk Decision	
Curi	rent Risk		Та	arget risk		
Likelihood	Impact	25	Likelihood	Impact	15	TREAT
5	5	20	3	5	10	

Appli

uencing Improving m resilience

Promoting h

Dashboard

icable Strategic Priorities	•
the wider determinants of health	X
nental well-being and building	\boxtimes
healthy behaviours	X
healthy future for the next through a focus on early years.	X
he public from infection and ntal threats to health	X
the development of a sustainable care system focused on and early intervention	\boxtimes
d mobilising knowledge and skills health and well-being across	\boxtimes

	EXISTING CONTROLS		SOURCES OF ASSURANCE	Level at which the Assurance is provided to						
No.	Control	Exec Owner	Assurance	Team / Division / Project / Programme	Directorate Team / Exec Lead	Business Exec Team / Sub Groups	Committ ee / Sub group	Board		
			BaHW agreed priorities document	Х	Х	Х		х		
5.1	Building a Healthier Wales programme		Building a Healthier Wales to receive spending plans against £7.2m allocations to Health Boards as part of their oversight role	x	х	х				
			BaHW Co-ordinating Group TOR and minutes	Х	Х	Х		х		
		Executive	BaHW Project Group TOR and minutes	X	Х	Х		Х		
5.2	Development of behaviour change capacity and skills	Director –	Update reports	x	x	х		x		
	Dialogue with Boards across Wales to	5	Biannual joint accountability meetings paperwork	X	Х	Х		Х		
5 0	support shift towards prevention and scale		Framework for Board to Boards	Х	Х	Х		Х		
5.3	up of evidence based interventions		Notes from Board to Boards	Х	Х	Х		х		
			IMTP	Х	Х	х		Х		

Due to Covid-19, all of the above controls and assurances are currently on hold. The assurance level will evaluated when decisions are made about future activities.

Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
5.3	Ensuring there is increasing		1	Establish baseline spend on prevention			
5.5	investment in prevention across the public sector		2	Develop a mechanism to track the spend on prevention			The adva
	Ensuring that additional investment in prevention is		3	Commission evaluation once for Wales			Hea CO\
5.3	spent in line with the evidence and results in improved outcomes		4	Building a Healthier Wales to establish mechanisms for oversight	Executive Director – Health and Wellbeing		
5.3	Galvanising voluntary sector resources for evidence based preventative interventions		5	Revised Terms of reference and work plan for CWW			
5.2	Development of behaviour		6	Successful recruitment to Programme Director Post		To be	
0.2	change capacity and skills		7	Grants/contracts awarded		determined	
5.1	Strengthen governance Irrangements with DPHS		8	Update MOUs with Health Boards	Deputy Chief Executive/ Executive Director of Operations Finance Board Secretary and Head of Board Business Unit		
			9	Update honorary contracts with DPHS	Executive Director – Health and Wellbeing Acting Director – People and Organisational Development		
New control identified relating to policy			10	Utilise the WHO CC to act as a policy think tank for WG and other Public Health stakeholders. Deliver the work plan of the WHO CC.	Director of Policy, Research and International Development	Ongoing	The work its fin Boan April throu Upda bene Vale close We a inter orga role agre WH0

Action Plan

Progress

e actions identified are intended to be vanced at a future point as Building a ealthier Wales is currently on hold due to DVID-19.

e WHO CC is progressing its agreed joint ork plan with WHO and has already submitted first annual report (2018/19) to WHO and our ard; and about to submit its second one in ril (2019/20). The WHO CC has also been rough scrutiny (Deep Dive, 2019 and Progress odate, 2020) at the KRIC. The WHO CC nefits to Wales, supporting Public Health ales system leadership role and working sely with Welsh Government, are apparent. are enabling and strengthening Wales' ernational 'influencer' role and our ganisational national and global leadership e through developing an emergent reements (MoU) between Wales and the HO going forward. As part of this, we are

Control Number	Gaps in controls	Gaps in assurance	Action Plan	Exec Lead	Due Date	
						appl publ Wald initia our v How fund in Ap cons proc In ac supp Gov Exal of Bi for in a fra impr redu work be in
New control identified relating to policy		1	Continue the periodic meetings with Cabinet Secretaries, Ministers and their officials across Government as appropriate in order to inform them on the work of Public Health Wales and support the application of health in all polices in their respective areas.	Chief Executive / Chair	Ongoing	Duri have Mee Tran Mee and Plan CO\

Action Plan

Progress

plying and developing further state of the art blic health tools and approaches first in ales. The Health Equity Status Report tiative is a key example of this (together with ir work on Evidencing Value/SROI and ACEs). owever, currently risk remains as much core nding for some key elements of this work ends April 2020. Further funding is being nsidered as part of the annual investment occesses.

addition, our policy work is being used to pport and inform the work of Welsh overnment and public health stakeholders. amples include a Health Impact Assessment Brexit, a report making the public health case investment in housing, and a report providing ramework for a preventative approach to proving winter health and wellbeing and ducing winter pressures in Wales. Our current orkplan include products that we anticipate will impactful, such as a Health Impact sessment on climate change.

uring 2020 the following meeting with Ministers ve taken place:

eeting with Deputy Minister for Economy and ansport on 13th January.

eeting with Minister for International Relations d the Welsh Language on 20th January.


anned scheduled of meetings on hold due to OVID-19.

	Thoro is a	risk that Public Health Wales will fail to secure and align resources to deliver its statutory	
Risk 6		ncluding its response to the COVID-19 pandemic. This will be caused by funding cuts or	Influencing the
NISK U		make required savings, secure funding (replaced generate income) or move resources organisation	Improving men resilience
			Promoting heal
		Sponsor and Assurance Group	Securing a hea
Executive S	ponsor	Huw George, Deputy Chief Executive / Director of Finance and Operations	generation thro
Assuring G	Group	Audit and Corporate Governance Committee	Protecting the period

Inherent Risk								
	Date		Likelihood:	3	Impact:	5	Score:	15

			Risk Score			Risk Decision
Curi	rent Risk		Т	arget risk		
Likelihood	Impact	15	Likelihood	Impact	10	TREAT
3	5	15	2	5	10	

		Risł	<pre>score</pre>			Risk Decision	Control Summary	No. of Controls	5	
Curre	nt Risk		Targ	get risk				No. of Assurances	18	
Likelihood	Impact		Likelihood	Impact		TREAT	Assurance		Weak Assurances	3
		16			8			Breakdown of Total	Moderate Assurances	1
	4		2	4			Summary	Assurance Rating	Strong Assurances	10
								C	No Assurances	4



Applic

- ving me ence oting he
- ring a he ration thi cting the
- onmenta Supporting th health and ca and early inte

Building and r to improve he Wales

Dashboard

cable Strategic Priorities	
he wider determinants of health	\mathbf{X}
ental well-being and building	X
ealthy behaviours	X
ealthy future for the next nrough a focus on early years.	X
e public from infection and al threats to health	X
he development of a sustainable are system focused on prevention ervention	X
mobilising knowledge and skills ealth and well-being across	X

	_		
ssurance			
ng			
lerate			
ak			
	-		

	Existing Con	trol		Leve	l at which	n the Assu	irance is pr	ovided to	
No.	Control	Exec Owner	Sources of Assurance	Team / Division / Project	Directorat e Team / Exec Lead	Business Exec Team / Sub Groups	Committee / Sub group	Board	Assessment of each assurance
			Welsh Government and Board approved Strategic Plan (IMTP)			Х		Х	Strong Assurance
			Board approved Annual Plan			Х		Х	Strong Assurance
		Deputy Chief Executive/Executive	Integrated Performance Report (Service/Finance/Quality/ People)			х	x	х	Strong Assurance
6.1	Public Health Wales	Director of	Monthly Finance Reports	X	X	Х			Weak Assurance
	Financial plan	Operations and	Monthly monitoring returns		X				Weak Assurance
		Finance	Directorate finance reports		X				Weak Assurance
			Annual accounts			Х	Х	Х	Strong Assurance
			Audits of financial systems and audit management			Х	Х		Strong Assurance
	Joint Executive Team		Integrated Performance Report (Service/Finance/Quality/ People)			х	x	x	Strong Assurance
6.2	meetings (currently paused due to Covid-19)	Executive Team	Mid and end of year Review Papers	X	X	Х			No Assurance
	paused due to Covid-19)		Joint Executive Team Report			Х		х	No Assurance
6.3	Quality and Delivery Meetings (currently paused due to Covid-19)	Deputy Chief Executive/Executive Director of Operations and Finance	Integrated Performance Report (Service/Finance/Quality/ People)			x		х	No Assurance
6.4	Mid and End of Year Reviews (currently paused due to Covid-19)	Executive Directors	Mid and End of year Review Reports		x	х		х	No Assurance
		Deputy Chief	Long Term Strategy - Working to achieve a healthier future for Wales			x		х	Strong Assurance
	Stratagia Driarity	Executive/Executive	Welsh Government and Board approved Strategic Plan (IMTP)			Х		Х	Strong Assurance
6.5	Strategic Priority Coordination Group	Director of	Board approved Annual Plan			Х		Х	Strong Assurance
		Operations and	Change control summary report			Х		Х	Moderate Assurance
		Finance	Integrated Performance Report (Service/Finance/Quality/ People)			x	x	Х	Strong Assurance

Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	
6.2, 6.4, 6.5	Outcome measures and performance metrics		1	Finalise outcome measures for our strategic priorities and organisation		March 2021	On hold due to have been dev Groups and we and Board. Du paused and wi COVID-19 res 2021 has been reviewed as th
6.1	Evidence of efficiency across the organisation		2	Monitor savings from organisational efficiency work streams		Ongoing	Continues to continues to m which includes
6.1	Model for monitoring savings and investments		3	Review organisational plans to enable resources to be redirected as required		March 2021	Initial exercise to support ph repeated alor Operating Plar
6.2, 6.3, 6.4, 6.5	Revised Performance Management Framework aligned to new Strategy and governance arrangements		4	Incorporate wider approach to value and impact into the organisations 12 month operating Plan	Deputy Chief Executive/Executive Director of Operations and	March 2022	Through deve operating plan will be incorpo
6.1	Covid-19 costs not included in 2020/2021 budget allocation		5	Secure funding from WG for COVID costs	Finance	December 2021	In progress. £ COVID-19 cos funding allocat September. Re Report/ Respo Board
6.1	Additional requirements not included in PHW IMTP 2020-23		6	Work up and submit BC's for new developments as a result of COVID (eg 24/7 working)		January 2021	Business case is currently bei January 2021.
6.1	Operational Plan 2020-21 did not include response to COVID-19		7	Development of a resourced organisational delivery plan for next 12 months		October 2020	On track

Action Plan

Progress

to COVID-19. Draft outcome measures eveloped through the Strategic Priority workshops held with the Executive Team Due to COVID-19 this work has been will be finalised when we stand down our esponse. A revised deadline of 31 March en included however this may need to be the pandemic response continues.

o be in progress. The Finance Team monitor progress against our Savings plans es organisational efficiency workstreams.

se undertaken to identify potential resources ohase 2 and 3 of plans. Exercise will be longside development of 12-18 month an.

velopment of the organisations 12 month an, value and impact is a key element that porated into our work going forward.

£10m non-pay and £1.3m pay to cover osts incurred to date. Confirmation of further cation expected from Welsh Government in Reported as part of Integrated Performance ponse Dashboard to Executive Team and


se for TAT approved. IP5 Lab 2 specification eing finalised and should be operation by 01 1.

		There is a risk that Public Health Wales will fail to deliver and effectively present accurate, relevant data/ statistics and/ or evidence based research/ evaluation to dynamically and actively inform and	Applicat
		maximise the impact of public health action especially relating to our response to COVDI-19. This	Influencing the wid
	Risk 8	will be caused by a lack of workforce capacity with the relevant skills and knowledge to rapidly respond to changing and increasing demands of COVID-19 and technological advances in data	Improving mental v resilience
		science; staff having an over-reliance on existing systems/procedures and a lack of sufficient change capacity.	Promoting healthy
L			Securing a healthy

	Sponsor and Assurance Group	through a focus on
	Sponsor and Assurance Group	Protecting the publ
Executive Sponsor	Sian Bolton (Transition Director – Knowledge)	environmental thre
Assuring Group	Knowledge Research and Information Committee	Supporting the dev
		health and care system

							Building and mobili
		erent R	ISK	1			improve health and
Date	Likelihood:	3	Impact:	4	Score:	12	

		Dial	· Coore			Diek Desision	Control Summary	No. of Controls	10	
		RISI	< Score			Risk Decision		No. of Assurances	23	
Curr	ent Risk		Target	risk			Assurance		Weak Assurances	3
Likelihood	Impact		Likelihood	Impact		Treat	Summary	Breakdown of Total	Moderate Assurances	8
1		16	2		8			Assurance Rating	Strong Assurances	6
4	4		2	4					No Assurance	6



Dashboard

Applicable Strategic Priorities	
Influencing the wider determinants of health	\boxtimes
Improving mental well-being and building resilience	\boxtimes
Promoting healthy behaviours	\boxtimes
Securing a healthy future for the next generation through a focus on early years.	\boxtimes
Protecting the public from infection and environmental threats to health	\boxtimes
Supporting the development of a sustainable health and care system focused on prevention and early intervention	\boxtimes
Building and mobilising knowledge and skills to improve health and well-being across Wales	\boxtimes

SSI	urance			
n	g			
de	rate			
ak				
	Control 8	3.9	Control 8.10	

	Existing Control		Sources of Assurance	Le Team /	evel at whi pr	rovided to	surance i	S	Assessment
No	Control	Exec Owner			Directorate Team / Exec Lead	Business Exec Team / Sub Groups	E Team Committe Sub e / Sub E group		of each Assurance
		Board Secretary & Head of Board Business Unit	Corporate Policy and Control Document Reviews – Corporate Register update reports to Committees	x	x	x	x	x	Moderate
8.1	Policies and procedures (including Standing Operating Procedures)	Transition Director -	Health Intelligence Division – Standard Operating Procedures (document development, review and approval) approved by the Director	x	x	x			Weak
		Knowledge	Research and Evaluation Division – Standard Operating Procedures (document development, review and approval) approved by the Director	x	x	x			Moderate
			Report to Committee on adherence to the Code of Practice for Statistics (UK Statistics Authority)	x	x	x	x		Moderate
8.2	Official Statistics National requirements		Independent Regulation (UK Statistics Authority) (reported to KRI Committee – currently not meeting due to COVID-19)	x	x	x	x		No assurance
0.2	Official Statistics National requirements	Transition Director -	External scrutiny (including UK Statistics Authority and Welsh Government) ensuring that correct process is followed. The Office of Statistics Regulation undertakes assessments, systematic reviews and compliance checks	x	x	x	x		Strong
		Knowledge	Report of Data Quality Management Task and Finish Group to KRIC – (Work suspended due to COVID)	х	x	x	x		No assurance
			Minutes and actions - Population Health Intelligence Network Steering Group (not currently meeting due to COVID-19)	x	x	x			No assurance
8.3	Quality Assurance processes		Written assurances from external data owners eg NWIS/ ONS re their quality assurance processes	x	x	x			Weak
			Evaluation of projects and programmes which are reported annually to the KRI Committee (Evaluations relating to COVID-19 currently reported to GOLD and/or BET)	x	x	x	x		No assurance
8.4	Corporate induction relating to confidentiality, Information Governance etc	Acting Director – People & Organisational Development	Knowledge Directorate compliance reported through the integrated performance report to Board	x	x	x	x	x	Strong
8.5	Skills and development training for specialist roles (e.g. analysts/ evidence reviewers)		Attendance at specialised training Specialist qualifications	x	x				Weak
			Notes/ Actions of monthly SMT meetings	X	x				Moderate
			Minutes/ Actions of Wider SMT meetings	X	X				Moderate
8.6	Directorate business systems & processes	Transition Director - Knowledge	Executive bi-monthly paper to the Business Executive Team on Knowledge Directorate alignment to Strategic Priorities (Currently suspended due to COVID-19)	x	x	x			No assurance
			Mid and End of Year reviews (to Chief Executive)	X	X	X			Moderate
8.7	Incident reporting system (data or research)		Information Governance Report detailing any data breaches	x	x	x	x		Moderate
8.8	Workforce Plan		Reports of progress against workforce plans (replaced with COVID-19 workforce plans at present)	x	x	x	x		Strong

Controls

	Existing Control		Sources of Assurance	Le	evel at whi pi	ch the Ass ovided to		is	Assessment
No	Control	Exec Owner		Team / Division / Project	Directorate Team / Exec Lead	Business Exec Team / Sub Groups	Committe e / Sub group	Board	of each Assurance
			Report to the People and OD Committee (as part of annual Integrated Medium Term Plan planning cycle) (POD Committee suspended at present due to COVID-19)	x	x	x	x		No assurance
8.9	Business Continuity arrangements		Business Continuity Action Plan (Knowledge Directorate)	X	X	Х			Strong
			Health and Care Standards reporting	X	X	X	X		Strong
8.1	0 Quality Management Systems		Clinical and Quality Audit Plan detailing local audits – bi-annual report to QSIC	x	x	x	x		Strong
			Mid and End of Year reviews (to Chief Executive)	X	X	X			Moderate

Controls

Control Number	Gaps in controls	Gaps in assurance	Action Plan	Exec Lead	Due Date	
8.1	Policies and procedures	Lack of Standard Operating Procedures (SOPs) for all processes within the Knowledge Directorate	Undertake base line of current SOPs in place within the Knowledge Directorate Identify gaps in relation to SOPs Develop SOPs that are required and a consistent approach for approval/ logging Disseminate to all Knowledge Directorate staff Review SOPs annual (ensure process in place to undertake review and log review)		To be determined	The actions future point a 19.
8.2	Official Statistics	Lack of audit (undertaken internally) to provide assurance that the process is adhered to	ernally) to provide surance that theStatistics produced, across the organization to confirm adherence to Official Statistics			The actions future point a 19.
8.3	Quality Assurance Processes	Lack of formal Standard Operating Procedures for Data Quality Management across all Directorates Lack of central register of assurances from external data owners eg NWIS etc	Collate baseline information and present data quality management report to KRI Committee. Identify gaps in relation to SOPs across the organisation relation to Data Quality Management Work with the relevant Directorates to ensure required SOPs are developed and disseminated as appropriate Create central register of assurances from external data owners	Transition Director/ Knowledge	To be determined	The actions future point
8.5	Skills and development training	Lack of dedicated data science team with appropriate skills, knowledge and experience	Skills requirement for Data Science Team determined Recruitment of data scientists with identified skills Data Science Strategy developed Capturing of minimal skills required at each level within the directorate for specialist roles (e.g. analysts and evidence reviewers)		To be determined	The actions future point a 19.
8.8	Workforce Plans	Lack of Data Analyst/ Scientist capacity to undertake surveillance on COVID-19	Implement recruitment plan identified by Workforce Work stream in Phase 2 Implementation Plan		October 2020	On Track.
8.10	Quality Management Systems	Lack of year on year plan for scheduled local audits within the Knowledge Directorate	Identify a rolling programme of audit to be completed internally for the Knowledge Directorate. This will then inform the organisational Clinical and Quality Audit Plan		To be determined	The actions future point a 19.

Action Plan

Progress

s identified are intended to be advanced at a t as this is currently on hold due to COVID-

s identified are intended to be advanced at a t as this is currently on hold due to COVID-

is identified are intended to be advanced at a nt as this is currently on hold due to COVID-19.

s identified are intended to be advanced at a at as this is currently on hold due to COVID-

s identified are intended to be advanced at a at as this is currently on hold due to COVID-

Strategic Risk Register – Risk 8 (COVID-19)

		Applie
	There is a risk that Public Health Wales will fail to effectively discharge its statutory responsibilities in protecting the public during the COVID-19 pandemic and ensure the organisation has an effective plan for recovery as the pandemic recedes	Influencing t health
	This will be caused by:	Improving n building resi
	 Failure to ensure that our role and responsibilities are clearly laid out, effectively communicated to partners and the public and that we frame our response and actions in accordance with these. This will require us to not accept activities that fall outside of our role that result in us vicariously accepting responsibility and accountability for actions that we do not have the authority to enact. 	Promoting h Securing a h generation t years.
Risk 8 (COVID)	Failure to sufficiently scale up our core response activities during the recovery phase of the pandemic in order to effectively support the system in Wales to protect the public, optimise outcomes for individuals and the population, facilitate the functioning of essential services and support the Welsh Government in the reviewing of social restrictions.	Protecting th environment Supporting t sustainable focused on p
	3. Failure to effectively balance the dynamics between responding to the ongoing pandemic- which remains the key priority of the organisation, fulfilling our broader statutory functions in relation to the population health (including the safe reactivation of services and functions), whilst preparing and responding to any resurgence in the transmission of coronavirus.	intervention Building and skills to imp across Wale
	Failure to effectively support the health and wellbeing of our staff within the current working environment and the challenges to remote working.	
	5. Failure to sufficiently influence policy and public health interventions.	

	Sponsor and Assurance Group
Executive Sponsor	Tracey Cooper, Chief Executive
Assuring Group	Board through the Business Executive Team

		Inh	erent l	Risk			
Date	10/08/2020	Likelihood:	4	Impact:	5	Score:	20

	Risk Score					Risk Decision
Curre	nt Risk		Targe	et risk		
Likelihood	Impact		Likelihood	ood Impact Tr		Treat
4	5	20	2	5	10	

Dashboard

Applicable Strategic Priorities	
encing the wider determinants of h	\boxtimes
oving mental well-being and ing resilience	\boxtimes
noting healthy behaviours	\boxtimes
ring a healthy future for the next ration through a focus on early s.	\boxtimes
ecting the public from infection and conmental threats to health	X
porting the development of a a a number of a a a number of a a system and care system sed on prevention and early vention	\boxtimes
ling and mobilising knowledge and to improve health and well-being ss Wales	\boxtimes

Strategic Risk Register – Risk 8 (COVID-19)

	Exist	ing Control		Lev	el at wh is p	ich the rovided		ance
No.	Control	Exec Owner	Sources of Assurance	Team / Division / Project	Directora te Team / Exec Lead	Busines s Exec Team / Sub Groups	Commi ttee / Sub group	Board
1.1	Organisational Governance Structure (Business Executive team, Board,	Executive Director Public Health Services / Medical Director	COVID-19 assurance reports and updates – formal reports (written or verbal) provided to all relevant meetings		Х	x	Х	х
	<i>Quality and Safety Committee, Audit and Corporate Governance Committee)</i>	Deputy Chief Executive, Executive Director Operations and Finance	Integrated performance report / performance and assurance dashboard		х	x	х	х
			Gold Terms of Reference			Х		
			Gold Minutes of meetings		Х	Х		
			Gold meeting papers		Х	Х		
	Incident response governance		Programme Delivery Confidence Assessment (weekly)			Х		Х
	arrangements	Executive Director Public Health Services /	Surveillance report (weekly)		Х	Х		
1.2	(Gold Group and Incident	Medical Director	IMT papers	Х	Х			
	Management team)		Daily sit rep reports		Х	Х		
			Daily surveillance data		Х	Х		
			PHE IMT minutes, papers and guidance		Х			
			Minutes, reports and Sitreps from respective cells / components of the governance structure	X	Х			
			Test, Trace, Protect Plan	Х	Х	Х	Х	Х
1.3	Emergency response plan	Chef Executive / Executive Director Public Health Services / Medical Director	Emergency Planning Framework			x	х	х
	Business continuity plans	Deputy Chief Executive, Executive Director	Business Continuity Framework			Х	Х	Х
	PHW business continuity	Operations and Finance /	PHW organisational recovery plan			Х		Х
1.4	frameworkCritical service continuity	Executive Director Public Health Services / Medical Director	Critical service level continuity plans			x		
	plans (screening, health protection, informatics)	Acting Director of People and Organisational Development	People Strategy / Workforce reports			х		х
1.5	Management of Welsh Government requests for advice	Transitional Director - Knowledge	Decision and Advice log	x	Х		Х	
1.6	WG strategic oversight Group for Test, Trace and Track (Programme Board)	Executive Director Public Health Services / Medical Director / Chief Executive	Minutes of meetings and papers		Х			
		Director of Policy and International Health, WHO	International evidence reviews		Х	Х		Х
		Collaborating Centre on Investment for Health and Well-being	Population 'How are we Doing' reports		Х	х		х
1.7	Learning and research	Strategic Responsible Officers (SRO) of workstream	Evaluations commissioned of key work-streams		Х	х		
		Transitional Director - Knowledge	Research team work programme for COVID-19		Х	Х		
		Executive Director Public Health Services / Medical Director	Consultation on key documents/operational models		Х	х		
1.8	Communication plans and activity	Deputy Chief Executive, Executive Director Operations and Finance	Analysis of communications performance external and internal		Х			

Strategic Risk Register – Risk 8 (COVID-19)

					1	I		
			Quality assurance arrangements in place to					
			provide accessible information for different	X	X			
			communication needs					
			Programme workstream updates / Sitreps		Х			
			Daily surveillance data published	Х	Х	Х		Х
			Weekly staff communications (often daily	x	x			
			communication)	~	~			
			Standard Operating Procedures			Х	Х	
	Health and Safety and Infection	Deputy Chief Executive, Executive Director	Monitoring of social distancing measures and		x			
1.9	Prevention assessments and	Operations and Finance /	process for PPE equipment		~			
1.9	control plan for workforce	Executive Director Quality, Nursing and Allied	Assessment undertaken of IPC needs re; COVID		x			
		Health Professionals	advice given from the HARP team		^			
			PPE stock control process implemented		Х			
	Implementation of guidance and	Deputy Chief Executive, Executive Director	Health and Safety Risk Assessments			Х	Х	
	policies to protect workforce (e.g.	Operations and Finance /	Staff Risk assessments			Х		Х
1.10	2 metre working guidance,	Executive Director Quality, Nursing and Allied	Workforce related COVID-19 policies updates			Х		Х
	remote working policies, HR	Health Professionals	Accurance reports			v		х
	policy variations) move to above		Assurance reports			Х		^
			Screening services reactivation – assurance and		x	x	x	x
			update papers		^	^	^	^
			UK and WG screening committee advice	Х	Х	Х		
			UK Joint Committee on vaccination and	x	x			
			immunisation	^	^			
	Monitoring of conditions to	Executive Director Public Health Services /	WG immunisation committee advice	Х	Х			
1.11	identify and reactivate statutory	Medical Director /	Welsh Health Circulars		Х	Х	Х	
	services not currently active	Transitional Director - Knowledge	Standard Operating Procedures – screening and	X	х			
			health protection	^	^			
			Accreditation reports	Х	Х	Х	Х	
			Public Health Wales Health Intelligence	X	x	x		
			Surveillance	^	^	^		
			Public Health Wales Health Protection Surveillance	Х	Х	Х		
1 1 2	Supply chain and procurement	Deputy Chief Executive, Executive Director	Weekly menitor and tracking status report			v		v
1.12	reports (sampling and testing)	Operations and Finance	Weekly monitor and tracking status report			X		Х
			People Strategy	Х	Х	Х		Х
		Acting Director of Decade and Organizational	Staff risk assessments	Х	Х	Х		Х
1.13	Workforce and resilience	Acting Director of People and Organisational	Staff communication (daily)	Х	Х	Х		
		Development	Recruitment Plans and delivery of new staffing	V	V	V		V
			posts	X	X	X		Х

	Action Plan						
Control Number	Gaps in controls	Gaps in assurance		Action Plan	Exec Lead	Due Date	Progress
1.1			1	Regular review of Board and Committee arrangements – reinstating key governance arrangements proportionate to the demands of the response	Chief Executive / Board Secretary and Head of Board Business Unit	Monthly review	
1.2			2	Periodically review the Gold group terms of reference to ensure relevance to the changing environment.	Executive Director Public Health Services / Medical Director / Board Secretary and Head of Board Business Unit	End October	
1.2		Oversight of Incident Management Team and supporting assurance reports	3	Review the terms of reference and operating arrangements for the Incident Management Team	Executive Director Public Health Services / Medical Director / Board Secretary and Head of Board Business Unit	End Nov	
1.2	<i>Key measures of performance</i>		4	Incorporate key measures to monitor the effectiveness of our work across the workstreams in the Implementation Plan for Test Trace Protect	Executive Director Public Health Services / Medical Director / workstream SROs		
1.4	<i>Revised Operating Plan (organisational)</i>		5	Develop and approve a revised Operating Plan	Executive Director Public Health Services / Medical Director / workstream SROs	End Oct	
1.6		Evidence based decision making	6	Undertake serial evaluation of the effectiveness of our communications	Deputy Chief Executive, Executive Director Operations and Finance	Ongoing	
1.6	Workforce capacity and capability		7	Source additional capacity to support the Communications Team including additional media management and strategic communications expertise	Deputy Chief Executive, Executive Director Operations and Finance	End October	
1.7		Evidence based decision making	8	Ensure that key operational aspects of the work are evaluated through the pandemic and learning applied	Transitional Director - Knowledge	Ongoing	
1.7		Evidence based decision making	9	Ensure that we use best available evidence to inform public health interventions through surveillance activity and international learning	Executive Director Public Health Services / Medical Director	Ongoing	
New	England led activities		10	Develop and agree action plan to ensure PHE led activities that impact on Wales can continue to be delivered.	Executive Director Public Health Services / Medical Director	End October	